MediWound Ltd. (MDWD) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture with both positive and negative aspects. The company shows strong partnerships and financial flexibility, but faces challenges like increased EBITDA loss and dependency on government contracts. The Q&A reveals optimism in sales estimates and market strategy but lacks transparency in revenue breakdown and contract timelines. Overall, the sentiment is neutral as positive elements are balanced by uncertainties and financial challenges.
Key Financial Performance
Revenue for Q3 2025 $5.4 million, up 23% year-over-year compared to $4.4 million for the same period in 2024. The increase was primarily driven by higher development services revenue, including additional contracts with DoD.
Gross Profit for Q3 2025 $0.9 million or 16.5% of revenue, compared to $0.7 million or 15.5% in the prior year period. The increase was due to a more favorable revenue mix.
R&D Expenses for Q3 2025 $3.5 million versus $2.5 million in Q3 2024, reflecting increased investment in the EscharEx VALUE Phase III study and related clinical activities.
SG&A Expenses for Q3 2025 $4 million compared to $3.2 million in the same period last year. The increase was primarily due to marketing authorization holder expenses.
Operating Loss for Q3 2025 $6.5 million compared to $5.1 million in Q3 2024. The increase was due to higher R&D and SG&A expenses.
Net Loss for Q3 2025 $2.7 million or $0.24 per share compared to a net loss of $10.3 million or $0.98 per share in Q3 2024. The improvement was mainly driven by noncash financial income from the revaluation of warrants this quarter compared to noncash financial expenses from warrant revaluation in Q3 2024.
Adjusted EBITDA Loss for Q3 2025 $5.4 million compared to a loss of $3.7 million in Q3 2024.
Revenue for First 9 Months of 2025 $15.1 million compared to $14.4 million in the same period of 2024. The increase was driven by higher development services revenue.
Gross Profit for First 9 Months of 2025 $3 million or 19.7% of revenue compared to $1.7 million or 12% in the first 9 months of 2024. The margin improvement was driven by a more favorable revenue mix.
R&D Expenses for First 9 Months of 2025 $9.8 million compared to $5.9 million in the same period of 2024, reflecting increased investment in clinical activities.
SG&A Expenses for First 9 Months of 2025 $10.6 million versus $9.1 million in the first 9 months of 2024. The increase was primarily due to marketing authorization holder expenses.
Operating Loss for First 9 Months of 2025 $17.5 million compared to $13.3 million in the same period of 2024.
Net Loss for First 9 Months of 2025 $16.7 million or $1.53 per share compared to $26.3 million or $2.72 per share in the same period of 2024. The reduction in net loss was primarily driven by noncash financial income from the revaluation of warrants in 2025 compared to noncash financial expenses from revaluation of warrants in 2024.
Adjusted EBITDA Loss for First 9 Months of 2025 $13.9 million compared to $9.9 million in the prior year period.
Cash Position as of September 30, 2025 $60 million in cash, cash equivalents and short-term deposits compared to $44 million at year-end 2024. The increase was due to a $30 million registered direct offering and $3.5 million in proceeds from Series A warrant exercises.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
EscharEx VALUE Phase III trial: Enrollment is progressing with a target of 216 patients across 40 sites in the US and Europe. Interim sample size assessment will occur after 65% of patients complete treatment. The trial focuses on complete debridement and wound closure, with potential annual peak sales estimated at $831 million.
Diabetic Foot Ulcer (DFU) program: Received positive FDA feedback and awaiting EMA advice. Study initiation planned for the second half of 2026.
NexoBrid: Expanded manufacturing facility completed, increasing production capacity 6x. Full operational capacity expected by year-end 2025. Record quarterly revenue in the US, up 38% year-over-year.
EscharEx market positioning: Medicare reduced reimbursement rates for skin substitute products, increasing EscharEx's attractiveness. A single legacy product in the enzymatic debridement segment generates $370 million annually.
NexoBrid global expansion: Approved in Australia for adult and pediatric patients, bringing total approved markets to 45 countries. Featured in 36 scientific presentations at the European Burn Association Congress.
NexoBrid manufacturing expansion: Expanded facility increases production capacity 6x, ensuring reliable supply and meeting global demand.
Financial position: Strengthened with $30 million equity financing, providing resources for long-term growth strategy.
BARDA collaboration: Multiyear program for stockpiling and development of new formulations paused due to government shutdown but expected to resume.
Corporate financial strategy: Improved cash position with $60 million in reserves, supporting strategic priorities and operational activities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
EscharEx VLU trial: Several EU sites required additional adjustments to meet ancillary-related regulatory requirements, creating potential uncertainty in the overall study timeline.
NexoBrid manufacturing expansion: The expansion process faced challenges such as a 2-year war, personnel drafting, and import delays on specialized equipment, which could have impacted timelines and operational efficiency.
BARDA collaboration: The U.S. government shutdown caused a pause in BARDA-related activities, creating uncertainty around the timing of BARDA and DOD-related revenue in Q4.
Financial performance: Operating loss increased to $6.5 million in Q3 2025 compared to $5.1 million in Q3 2024, and adjusted EBITDA loss also widened, reflecting higher R&D and SG&A expenses.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
EscharEx VALUE Phase III trial: Enrollment is progressing with a target of 216 patients across 40 sites in the US and Europe. Interim sample size assessment will occur after 65% of patients complete treatment. The company plans to initiate a diabetic foot ulcer study in the second half of 2026.
NexoBrid manufacturing expansion: The expanded manufacturing facility is expected to reach full operational capacity by year-end 2025, with regulatory review determining the timing of commercial output.
BARDA collaboration: Activities related to stockpiling and development of new formulations are expected to resume following the end of the government shutdown.
EscharEx market potential: Updated U.S. market access and pricing assessment estimates annual peak sales of $831 million, supported by robust clinical data and health economic benefits.
NexoBrid commercial growth: Production capacity has increased sixfold, and the product has been approved in 45 countries. U.S. partner Vericel plans to pursue a permanent CPT code by 2027.
Financial outlook: The company has $60 million in cash and expects this to provide financial flexibility to advance key programs and execute strategic priorities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the reason for the increase in the U.S. peak sales estimate for EscharEx from $725 million to $830 million?
A:The increase in the U.S. peak sales estimate for EscharEx is due to a market access-focused analysis that emphasized pricing. The baseline price was initially set at a 15% increase over SANTYL, but with HEOR benefits, the price could go up to as much as 50% over SANTYL. A conservative estimate between the base and top case was used, resulting in the $831 million peak sales figure.
Q:Will the same centers enrolling the VLU study be used for the DFU study?
A:No, the centers for the DFU study will be different from those used for the VLU study. The company is waiting for EMA feedback to ensure alignment with regulators before finalizing the study design.
Q:What is the breakdown of the $830 million projection between DFU and VLU opportunities?
A:The split is roughly even, with a slight weighting towards venous leg ulcers (VLU) due to the pain issue associated with VLUs, which makes them less likely to be debrided with surgical methods. Diabetic foot ulcers (DFU) are more often debrided surgically due to peripheral neuropathy, but EscharEx is expected to gain share due to its ability to reduce the time to complete debridement.
Q:What is the status of the BARDA contract and its potential impact?
A:The BARDA contract has not yet been awarded. The RFP covers stockpiling, room temperature stable formulations, and trauma blast injury solutions. The program is expected to extend for up to 10 years, and Vericel is leading the effort in the U.S. MediWound is providing full support. The company is waiting for the U.S. government to resume normal operations after the shutdown to move forward.
Q:How does the lack of a permanent CPT code impact adoption, and what benefits would a permanent CPT code provide?
A:The lack of a permanent CPT code does not significantly impact adoption since procedures are done inpatient through DRG. However, a permanent CPT code would provide legitimacy, drive physician adoption, and facilitate institutional acceptance by standardizing language, aiding internal approval pathways, and making it easier for burn centers to approve and contract NexoBrid.
Q:Can you provide a breakdown of the $5.4 million in revenue for the quarter?
A:The company did not provide a detailed breakdown of the $5.4 million in revenue for the quarter. However, the gross margin improved to 20% from 12% last year, reflecting a favorable change in revenue mix. The gross margin is expected to gradually move towards 25% at full capacity.
Q:What are the commercialization plans and expansion into Europe?
A:The company is currently limited by its manufacturing capacity, which is expected to be fully operational by the end of 2025. Once operational, the company plans to disclose its commercial plans for expansion into Europe.
Q:What endpoints are most relevant to the health economic benefit of EscharEx, and are there specific thresholds in Phase III to justify upside pricing?
A:The most relevant endpoint is early wound closure, which reduces costs associated with nursing time, physician time, product use, and risks like infection and hospitalization. The company is modeling pricing conservatively, with a cap at a 50% premium over SANTYL, based on payer feedback and HEOR benefits.
Q:What factors might lead physicians to opt for other methods like sharp or autolytic debridement instead of EscharEx?
A:Physicians might opt for sharp debridement in cases of peripheral neuropathy in diabetic foot ulcers, where it may be easier to clean the wound with a knife. Autolytic debridement is less expensive and may be chosen depending on the setting, case situation, and patient insurance. EscharEx is expected to take significant share from autolytic debridement but not completely replace it.
Q:Review of Unclear Management Responses
A:Management avoided providing a detailed breakdown of the $5.4 million in revenue for the quarter, citing the lack of a full financial statement for the third quarter. Additionally, they did not provide a specific timeline for the BARDA contract award, only stating that they are waiting for the U.S. government to resume normal operations.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Association Congress
Australia use
BARDA RFP
BLA pathway
CPT code
Congress presentation
DFU validation
DOD component
EMA advice
EU adjustment
EU site
EscharEx MediWound
EscharEx VLU
EscharEx biologic
EscharEx health
EscharEx result
European Burn
Gonen Chief
Phase III
ability
financials
financing
health care
improvement
income revaluation
loss month
momentum
month period
noncash income
period increase
period loss
phase
priority
share period
shutdown
stage
term
warrant revaluation
wound closure
MDWD Transcript
MediWound Ltd. (MDWD) Q1 2026 Earnings Call Transcript
Unknown5-27
The earnings call summary presents a mixed outlook. The reaffirmation of revenue guidance and ongoing clinical developments are positive, but uncertainties in regulatory approvals and manufacturing expansions pose risks. The Q&A reveals potential delays and a lack of specific details on key contracts, which may cause investor concern. Overall, despite some promising developments, the lack of clarity and potential operational challenges lead to a neutral sentiment.
MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript
Unknown3-5
The earnings call presents a mixed outlook. Positive elements include increased manufacturing capacity and potential market opportunities for EscharEx. However, challenges such as higher EBITDA losses, revenue guidance reliance on uncertain contracts, and management's lack of transparency in specific financial contributions temper optimism. The Q&A session highlights demand uncertainties and geopolitical risks, further contributing to a neutral sentiment. Without the market cap, it's difficult to predict volatility, but the mixed signals suggest a neutral stock price movement in the short term.
MediWound Ltd. (MDWD) Q3 2025 Earnings Call Transcript
Unknown11-20
The earnings call summary presents a mixed picture with both positive and negative aspects. The company shows strong partnerships and financial flexibility, but faces challenges like increased EBITDA loss and dependency on government contracts. The Q&A reveals optimism in sales estimates and market strategy but lacks transparency in revenue breakdown and contract timelines. Overall, the sentiment is neutral as positive elements are balanced by uncertainties and financial challenges.
MediWound Ltd. (MDWD) Q2 2025 Earnings Call Transcript
Unknown8-14
The earnings call presented mixed signals. While strategic collaborations and funding are positive, the decline in revenue and increased operating loss are concerning. The Q&A highlighted ongoing projects and potential future benefits but also revealed some uncertainties, particularly regarding patient recruitment and manufacturing timelines. Despite some positive developments, the overall financial health and lack of immediate catalysts suggest a neutral market reaction.
MDWD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
